Table 4.

Associations of extracellular vesicle proteins and number of affected vascular territories

ProteinNumber of affected vascular territories (sum score)History/presence of diseaseHistory/presence of disease, adjusted
Cystatin C1.1 (0.76–1.7)1.1 (0.67–1.8)1.1 (0.65–1.9)
CD142.4 (1.4–4.1)3.6 (1.8–7.1)3.4 (1.6–7.3)
α2-Antiplasmin1.1 (0.93–1.3)1.1 (0.93–1.4)1.1 (0.89–1.4)
ProteinNumber of affected vascular territories (sum score)History/presence of diseaseHistory/presence of disease, adjusted
Cystatin C1.1 (0.76–1.7)1.1 (0.67–1.8)1.1 (0.65–1.9)
CD142.4 (1.4–4.1)3.6 (1.8–7.1)3.4 (1.6–7.3)
α2-Antiplasmin1.1 (0.93–1.3)1.1 (0.93–1.4)1.1 (0.89–1.4)

Values are odds ratio (95% confidence interval) for increased number of vascular affected territories per unit increase of proteins. All values are adjusted for age, gender, body mass index, low-density lipoprotein, smoking, diabetes, hypertension, glomerular filtration rate, platelet aggregation inhibitor use, and statin use. Additional adjustments are for atherosclerosis parameters (ankle–brachial index, common carotid intima–media thickness, carotid stenosis, abdominal aorta diameter).

Table 4.

Associations of extracellular vesicle proteins and number of affected vascular territories

ProteinNumber of affected vascular territories (sum score)History/presence of diseaseHistory/presence of disease, adjusted
Cystatin C1.1 (0.76–1.7)1.1 (0.67–1.8)1.1 (0.65–1.9)
CD142.4 (1.4–4.1)3.6 (1.8–7.1)3.4 (1.6–7.3)
α2-Antiplasmin1.1 (0.93–1.3)1.1 (0.93–1.4)1.1 (0.89–1.4)
ProteinNumber of affected vascular territories (sum score)History/presence of diseaseHistory/presence of disease, adjusted
Cystatin C1.1 (0.76–1.7)1.1 (0.67–1.8)1.1 (0.65–1.9)
CD142.4 (1.4–4.1)3.6 (1.8–7.1)3.4 (1.6–7.3)
α2-Antiplasmin1.1 (0.93–1.3)1.1 (0.93–1.4)1.1 (0.89–1.4)

Values are odds ratio (95% confidence interval) for increased number of vascular affected territories per unit increase of proteins. All values are adjusted for age, gender, body mass index, low-density lipoprotein, smoking, diabetes, hypertension, glomerular filtration rate, platelet aggregation inhibitor use, and statin use. Additional adjustments are for atherosclerosis parameters (ankle–brachial index, common carotid intima–media thickness, carotid stenosis, abdominal aorta diameter).

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close